Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.

ABSTRACT:

Background

Although peanut oral immunotherapy (OIT) has been conclusively shown to cause desensitization, it is currently unknown whether clinical protection persists after stopping therapy.

Objective

Our primary objective was to determine whether peanut OIT can induce sustained unresponsiveness after withdrawal of OIT.

Methods

We conducted a pilot clinical trial of peanut OIT at 2 US centers. Subjects age 1 to 16 years were recruited and treated for up to 5 years with peanut OIT. The protocol was modified over time to permit dose increases to a maximum of 4000 mg/d peanut protein. Blood was collected at multiple time points. Clinical end points were measured with 5000-mg double-blinded, placebo-controlled food challenges once specific criteria were met.

Results

SUBMITTER: Vickery BP 

PROVIDER: S-EPMC3960331 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature